Sixty clinical-stage psychedelic drug stocks research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances of which 12, with market capitalizations of $50M or more, are constituents of the non-tradable munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index and that index has declined -10.6% in the last 2 weeks albeit up +7.8% since the end of September.

Seven of the constituents have declined so far in November, 2 are unchanged in price, and 3 have advanced, as follows:

The Losers Are:

1. Mydecine (MYCOF): DOWN -33.3%
2. Compass (CMPS): DOWN -16.1%
3. GH Research (GHRS): DOWN -12.6%
4. Field Trip (FTRP): DOWN -10.8%
5. Small Pharma (DMTTF): DOWN -6.8%
6. Numinus (LKYSF): DOWN -1.7%

The Winners Are:

1. Awakn (AWKNF): UP +1.3% (Read: Awakn Life Sciences: Wake Up To The Huge Potential)
2. atai (ATAI): UP +2.3%
3. Cybin (CYBN): UP +2.7%

Red Light Holland (TRUFF) and Seelos (SEEL) remained unchanged in price.

Action Going Forward

You are encouraged to click on the hyperlinked symbols above of those stocks you are interest in and review their latest financial statements and commentary as found in the TalkMarkets data there.